Related Experiment Video

Updated: May 2, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

11.2K

Pancreatic neuroendocrine tumors: does chemotherapy work?

Mohamedtaki Abdulaziz Tejani1, Muhammad Wasif Saif

  • 1Division of Hematology and Oncology, University of Rochester. Rochester, NY, USA. mohamed_tejani@urmc.rochester.edu.

JOP : Journal of the Pancreas
|March 13, 2014
PubMed

Insights

Combination capecitabine and temozolomide shows promise for advanced pancreatic neuroendocrine tumors (pNETs). This regimen may offer a new option for patients with metastatic pNET, addressing limitations of current treatments.

Area of Science:

  • Oncology
  • Gastroenterology
  • Medical Oncology

Background:

  • Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms with variable prognosis.
  • Current treatments for advanced, unresectable pNETs include somatostatin analogs, everolimus, and sunitinib.
  • Existing systemic therapies have limitations in response rates and toxicity, necessitating novel treatment strategies.

Framework:

  • This review focuses on three abstracts presented at the 2014 ASCO Gastrointestinal Cancers Symposium.
  • The abstracts evaluate the efficacy and safety of combination capecitabine and temozolomide therapy.
  • The study population comprises patients with advanced, unresectable pancreatic neuroendocrine tumors.

Implementation:

  • Combination capecitabine and temozolomide was administered to patients with advanced pNET.
  • Outcomes such as response rates, progression-free survival, and toxicity were assessed.
  • Data from the three abstracts were summarized to provide a comprehensive overview.

Implications:

  • The combination of capecitabine and temozolomide demonstrates potential as a treatment option for advanced pNET.
  • This regimen may represent a valuable addition to the treatment algorithm for metastatic pNET.
  • Further investigation into this combination therapy is warranted to optimize its role in clinical practice.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
563
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927